<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380220</url>
  </required_header>
  <id_info>
    <org_study_id>972/17</org_study_id>
    <secondary_id>PE-2013-02357745</secondary_id>
    <nct_id>NCT04380220</nct_id>
  </id_info>
  <brief_title>Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis</brief_title>
  <official_title>Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Elena Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regina Elena Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective, controlled study. MS patients (1° group: 30 patients in
      relapse; 2° group: 30 patients in remission) and age/sex-matched healthy controls (3° group:
      30 subjects) will be enrolled in the study. Patients' disability level will be evaluated by
      EDSS and MSFC.

      Patients and controls will be tested for either coagulation/complement (C3, C4, C4a, C9,
      fibrinogen, factor VIII and X, D-dimer, protein C, protein S, antithrombin, factor II, aPTT,
      von-Willebrand factor), soluble markers of endothelial damage (thrombomodulin, Endothelial
      Protein C Receptor), antiphospholipid antibodies, lupus anticoagulant, complete blood count,
      viral serological assays or microRNA microarray.

      Patients will undergo dynamic susceptibility contrast-enhanced MRI using a 3.0-T scanner to
      evaluate CBF, CBV, MTT, lesion number and volume.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 7, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>plasma concentration of coagulation factor</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Factor VIII (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentration of coagulation factor</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Factor X (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentration of coagulation factor</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>D-dimer (ng/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentration of coagulation factor</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Protein C (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentration of coagulation factor</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Protein S (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentration of coagulation factor</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Fibrinogen (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>plasma concentration of coagulation factor</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>complement (mg/dl)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain MRI hemodynamic changes at DSC 3.0-T MRI</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>cerebral blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain MRI hemodynamic changes at DSC 3.0-T MRI</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>cerebral blood volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain MRI hemodynamic changes at DSC 3.0-T MRI</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>mean transit time</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Relapse</condition>
  <arm_group>
    <arm_group_label>Relapsing MS patients</arm_group_label>
    <description>Patients diagnosed with relapsing-remitting multiple sclerosis and in relapse, untreated or treated with only immunomodulatory therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remitting MS patients</arm_group_label>
    <description>Patients diagnosed with relapsing-remitting multiple sclerosis and in remission, untreated or treated with only immunomodulatory therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Age- and sex-matched healthy control subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood samples and processing</intervention_name>
    <description>DSC perfusion technique at 3.0-T MRI only in MS patients</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Relapsing MS patients</arm_group_label>
    <arm_group_label>Remitting MS patients</arm_group_label>
    <other_name>complement C3, C4, C4a, C9, fibrinogen, factor VIII and X, D-dimer, protein C, protein S, antithrombin, aPTT, factor II, v-Willebrand factor, thrombomodulin, Endothelial Protein C Receptor</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum/plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Relapsing-remitting multiple sclerosis patients and healthy subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed with relapsing-remitting multiple sclerosis, untreated or treated
             with only immunomodulatory therapy, in relapse o in remission

        Exclusion Criteria:

          -  pregnant, with any neoplastic, hematologic, thyroid, metabolic, thrombotic or
             autoimmune disease, drug or alcohol addicted, treated with immunosuppressive drugs,
             steroids o any medication interfering with coagulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Regina Elena National Cancer Institute</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rome Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regina Elena Cancer Institute</investigator_affiliation>
    <investigator_full_name>Tatiana Koudriavtseva</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>relapse</keyword>
  <keyword>coagulation</keyword>
  <keyword>complement</keyword>
  <keyword>cerebral blood flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protein C</mesh_term>
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Protein S</mesh_term>
    <mesh_term>Factor VIII</mesh_term>
    <mesh_term>Complement C3</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

